Results 221 to 230 of about 141,907 (307)

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1mut) are among the most common mutations in acute myeloid leukemia (AML) and have historically been considered favorable‐risk in the absence of FLT3‐ITD. In the European LeukemiaNet (ELN) 2024 risk‐classification for patients treated with hypomethylating agents plus venetoclax (HMA + VEN),
Fieke W. Hoff   +44 more
wiley   +1 more source

Quizartinib in Combination With FLAG‐IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG‐QUIDA): A PETHEMA Phase I‐II Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal   +29 more
wiley   +1 more source

Association of maternal immunoglobulin G levels with pregnancy outcomes in primary immunodeficiency: A retrospective single-center study. [PDF]

open access: yesMedicine (Baltimore)
Gerek ME   +9 more
europepmc   +1 more source

Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments (PQRST)” Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic ...
Betty K. Hamilton   +11 more
wiley   +1 more source

Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt   +8 more
wiley   +1 more source

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Hydroxyurea (HU) is the most widely prescribed disease‐modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with homozygous sickle cell disease (HbSS).
Sigrid van der Veen   +26 more
wiley   +1 more source

Update on occupational contact urticaria: a systematic narrative review. [PDF]

open access: yesCurr Opin Allergy Clin Immunol
Bizjak-Suran M   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy